摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(4-isopropoxyphenyl)ethanol | 86817-77-8

中文名称
——
中文别名
——
英文名称
2-(4-isopropoxyphenyl)ethanol
英文别名
2-(p-isopropoxyphenyl)ethanol;2-(4-propan-2-yloxyphenyl)ethanol
2-(4-isopropoxyphenyl)ethanol化学式
CAS
86817-77-8
化学式
C11H16O2
mdl
——
分子量
180.247
InChiKey
IVMMFYBOPVQEIK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    13
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.45
  • 拓扑面积:
    29.5
  • 氢给体数:
    1
  • 氢受体数:
    2

SDS

SDS:0773465e51b842426e23cadcd2332a37
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-(4-isopropoxyphenyl)ethanol碘甲烷 在 sodium hydride 作用下, 以 四氢呋喃 为溶剂, 以92%的产率得到2-(p-isopropoxyphenyl)ethyl methyl ether
    参考文献:
    名称:
    Pearson, Anthony J.; Rees, David C.; Thornber, Craig W., Journal of the Chemical Society. Perkin transactions I, 1983, p. 619 - 624
    摘要:
    DOI:
  • 作为产物:
    描述:
    (4-异丙氧基苯基)乙酸硼烷 作用下, 以 四氢呋喃 为溶剂, 以100%的产率得到2-(4-isopropoxyphenyl)ethanol
    参考文献:
    名称:
    Pearson, Anthony J.; Rees, David C.; Thornber, Craig W., Journal of the Chemical Society. Perkin transactions I, 1983, p. 619 - 624
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF
    申请人:FUJIFILM Corporation
    公开号:US20160168139A1
    公开(公告)日:2016-06-16
    There is provided a morpholine derivative represented by General Formula [1A] or a salt thereof. (In the formula, a ring A represents a ring represented by General Formula [I]; * represents a bonding position; Z 2 represents CH or the like; Z 1 represents CR 6 or the like; R 6 represents a hydrogen atom or the like; X 1 represents CHR 7 or the like; R 7 represents a hydrogen atom or the like; X 2 represents CH 2 or the like; R 1 and R 2 are the same as or different from each other, and each of R 1 and R 2 represents a hydrogen atom or the like; R 3 , R 4 , and R 5 are the same as or different from each other, and each of R 3 , R 4 , and R 5 represents a hydrogen atom, NR a R b , or the like; and each of R a and R b represents a hydrogen atom, a C 1-8 alkyl group which may have a substituent, or the like.)
    提供一种由通用式[1A]表示的吗啉衍生物或其盐。 (在该式中,环A代表由通用式[I]表示的环;*代表连接位置;Z 2 代表CH或类似物;Z 1 代表CR 6 或类似物;R 6 代表氢原子或类似物;X 1 代表CHR 7 或类似物;R 7 代表氢原子或类似物;X 2 代表CH 2 或类似物;R 1 和R 2 相同或不同,且R 1 和R 2 中的每一个代表氢原子或类似物;R 3 ,R 4 和R 5 相同或不同,且R 3 ,R 4 和R 5 中的每一个代表氢原子,NR a R b 或类似物;R a 和R b 中的每一个代表氢原子,可能具有取代基的C 1-8 烷基基团,或类似物。)
  • Urea Glucokinase Activators
    申请人:Lau Jesper
    公开号:US20090105482A1
    公开(公告)日:2009-04-23
    The invention provides a compound of general formula (I) wherein the substituents are defined further in the application, as well as further embodiments hereof described in the attached embodiments. The present invention also provides use of the compounds of the invention for preparation of a medicament for the treatment of various diseases, e.g. for the treatment of type 2 diabetes.
    本发明提供了一种具有一般式(I)的化合物,其中取代基在申请书中进一步定义,以及在所附的实施例中进一步描述的本发明的其他实施例。本发明还提供了使用该化合物制备药物治疗各种疾病的用途,例如治疗2型糖尿病。
  • Substituted acrylamide derivative and pharmaceutical composition comprising the same
    申请人:Daiichi Sankyo Company, Limited
    公开号:US08143446B2
    公开(公告)日:2012-03-27
    A pharmaceutical composition comprising a compound having Formula (I) or a pharmacologically acceptable salt thereof as an active ingredient: [wherein, R1 is, for example, a C6-C10 aryl group which may be substituted with one group or more than one group selected from substituent group α; R2 is, for example, a C6-C10 aryl group which may be substituted with one group or more than one group selected from substituent group α; and X is, for example, a hydroxyl group or a C1-C6 alkoxy group].
    一种药物组合物,包括以下化合物或其药理学上可接受的盐作为活性成分:[其中,R1是C6-C10芳基,可以被取代为一个或多个取代基α;R2是C6-C10芳基,可以被取代为一个或多个取代基α;X是羟基或C1-C6烷氧基。]
  • Substituted Acrylamide Derivative and Pharmaceutical Composition Comprising the Same
    申请人:Aoki Kazumasa
    公开号:US20120220593A1
    公开(公告)日:2012-08-30
    A pharmaceutical composition comprising a compound having Formula (I) or a pharmacologically acceptable salt thereof as an active ingredient: [wherein, R 1 is, for example, a C 6 -C 10 aryl group which may be substituted with one group or more than one group selected from substituent group α; R 2 is, for example, a C 6 -C 10 aryl group which may be substituted with one group or more than one group selected from substituent group α; and X is, for example, a hydroxyl group or a C 1 -C 6 alkoxy group].
    一种制药组合物,包括具有式(I)或其药理学上可接受的盐作为活性成分的化合物:[其中,R1是例如C6-C10芳基基团,该基团可以被选自取代基α的一个或多个基团替代;R2是例如C6-C10芳基基团,该基团可以被选自取代基α的一个或多个基团替代;X是例如羟基或C1-C6烷氧基。]
  • Urea glucokinase activators
    申请人:NOVO NORDISK A/S
    公开号:EP2377856A1
    公开(公告)日:2011-10-19
    The invention provides a compound of general formula (1) wherein the substituents are defined futher in the application, as well as further embodiments hereof described in the attached embodiments. The present invention also provides use of the compounds of the invention for preparation of a medicament for the treatment of various diseases, e.g. for the treatment of type 2 diabetes.
    本发明提供了通式(1)的化合物 其中取代基在本申请中进一步定义,以及在所附实施例中描述的本发明的进一步实施例。 本发明还提供了本发明化合物用于制备治疗各种疾病的药物的用途,例如用于治疗 2 型糖尿病。
查看更多